Compare Abeona Therapeutics Inc (ABEO) vs Honeywell International Inc (HON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Honeywell International Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Honeywell International Inc trades at $221.53 (market cap $71.30B). The key difference: Honeywell International Inc is far larger — about 191× Abeona Therapeutics Inc's market cap, and Honeywell International Inc pays a 4.23% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HON | |
|---|---|---|
Market Cap | $373.32M | $71.30B |
Sector | Health | Industrials |
52-Week High | $7.23 | $248.04 |
52-Week Low | $4.17 | $188.14 |
Enterprise Value | $228.22M | $95.65B |
Dividend Yield | — | 4.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Honeywell Technologies (HON) trades at $225.05, down 2.09% today, following the completion of its aerospace spinoff on June 29, 2026. The stock shows strong fundamentals with a P/E of 18.46 and consistent earnings beats in recent quarters. Technical indicators suggest a bullish trend with support at $225 and resistance at $234. The company maintains solid profitability with 10.89% net margins and 26.41% ROE, though revenue declined slightly to $37.44B in 2025.
The outlook remains positive with 64% analyst buy ratings and a $402.40 consensus price target, representing 79% upside potential. Key risks include integration challenges from recent spinoffs and rising debt-to-asset ratio (46.65% in 2025). The company's focus on high-growth automation segments and ESG alignment provides long-term growth catalysts, though near-term volatility may persist during the post-spinoff transition period.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
